NB protein does not affect influenza B virus replication in vitro and is not required for replication in or transmission between ferrets

Ruth A. Elderfield, 1 Marios Koutsakos, 1 † Rebecca Frise, 1 Konrad Bradley, 1 ‡ Jonathan Ashcroft, 1 $ Shanhjahan Miah, 2 Angie Lackenby 2 and Wendy S. Barclay 1

The influenza B virus encodes a unique protein, NB, a membrane protein whose function in the replication cycle is not, as yet, understood. We engineered a recombinant influenza B virus lacking NB expression, with no concomitant difference in expression or activity of viral neuraminidase (NA) protein, an important caveat since NA is encoded on the same segment and initiated from a start codon just 4 nt downstream of NB. Replication of the virus lacking NB was not different to wild-type virus with full-length NB in clonal immortalized or complex primary cell cultures. In the mouse model, virus lacking NB induced slightly lower IFN-α levels in infected lungs, but this did not affect virus titres or weight loss. In ferrets infected with a mixture of viruses that did or did not express NB, there was no fitness advantage for the virus that retained NB. Moreover, virus lacking NB protein was transmitted following respiratory droplet exposure of sentinel animals. These data suggest no role for NB in supporting replication or transmission in vivo in this animal model. The role of NB and the nature of selection to retain it in all natural influenza B viruses remain unclear.

INTRODUCTION

Seasonal influenza illness results from infection of the upper respiratory tract epithelium by influenza A or B viruses. Influenza B viruses are generally less well studied than influenza A viruses and do not give rise to pandemics as they have no sustained animal reservoir (Jackson et al., 2011). Nonetheless, influenza B viruses cause a significant number of annual influenza cases and the divergence of two antigenically distinct lineages of influenza B virus has necessitated the recent inclusion of two antigenically distinct lineages of influenza B virus into the annual vaccine, resulting in a quadrivalent product (Belshe, 2010; Rota et al., 1990).

Influenza A and B viruses are orthomyxoviruses; both have two glycoproteins on the surface of the viral membrane, haemagglutinin (HA) and neuraminidase (NA), which are involved in viral entry, by binding sialic acid receptors, and release of progeny viruses, by cleaving sialic acid, respectively. The M2 protein is a third, minor membrane component of the influenza A virus particle. M2 is an ion channel protein and has several roles in the influenza A replication cycle, including disassembly, assembly and scission, as well as modification of the autophagy pathway and activation of the inflammasome (Gannage et al., 2009; Hughley et al., 1995; Ichinohe et al., 2010; Iwatsuki-Horimoto et al., 2006; McCown & Pekosz, 2005; Rossman et al., 2010). Influenza B viruses encode a homologue known as BM2 with an ion channel similar in function to that of influenza A M2, required for uncoating and with a role in assembly of the influenza B virus particle (Horvath et al., 1990; Imai et al., 2004; Pinto et al., 1992). Influenza B viruses uniquely encode a fourth surface glycoprotein, the NB protein (Shaw et al., 1983).

NB is encoded by segment six of the influenza B virus, the same segment that encodes NA. The NB open reading frame overlaps that of NA, and the two AUG start codons are separated by only four nucleotides, with the NB start codon being closer to the 5’ end of the mRNA (Shaw et al., 1983).

NB is an integral membrane protein of 100 amino acids, found on the surface of infected cells (Brassard et al., 1996). It has an 18 amino acid extracellular N terminus, a 22 amino acid transmembrane domain and a 60 amino acid cytoplasmic C terminus. There are two glycosylation sites on the extracellular domain that acquire high mannose sugars during post-translational processing.

†Present address: Peter Doherty Institute, Melbourne, Australia.
‡Present address: Crick Institute, Mill Hill, London, UK.
$Present address: Addenbrooke’s Hospital, University of Cambridge, UK.
Multiple N-acetyl-lactosamine residues (Gal[β1→4-GlcNAc
β1→3) are added to these carbohydrates to form complex structures, termed polylactosamineglycans (Williams & Lamb, 1986, 1988). The NB glycoprotein forms a tetramer at the infected cell surface and is incorporated in the virion during budding but only in relatively small numbers (approximately 15–100 molecules per virion) (Betakova et al., 1996; Brassard et al., 1996).

The function of NB is currently unknown. The similarity of domain organization of NB and M2 proteins originally led to suggestions that NB may act as the functional homologue for the influenza A virus M2 ion channel and that NB may act as the functional homologue for the influenza A virus M2 ion channel and data derived from voltage conductance studies supported this notion (Betakova et al., 1996; Fischer et al., 2000, 2001; Premkumar et al., 2004; Sunstrom et al., 1996). However, the discovery that BM2, a protein encoded on influenza B virus RNA segment seven, served as the influenza B virus ion channel discounted this. Therefore, it is likely that NB serves an alternative function for influenza B virus. Hatta and Kawaoka used reverse genetics to produce recombinant influenza B viruses that lacked NB, indicating that the protein is not essential for virus viability. Indeed, viruses lacking NB replicated as well as WT virus in Madin Darby Canine Kidney (MDCK) cells. Conversely, in BALB/c mice the replication of the mutant viruses was restricted compared to the WT (Hatta & Kawaoka, 2003).

To engineer the mutations that abrogated NB expression, Hatta and Kawaoka disrupted sequences around and including the NB AUG start codon. However, given the close proximity of the start codon of NB to that of the essential viral protein NA, it was not clear whether the attenuated phenotype observed in mice for the NB deletions might result from an effect on NA expression (Williams & Lamb, 1989).

We therefore wanted to pursue the investigation of the role of the NB protein by using an NB mutant with intact NA gene expression. To achieve that, a novel mutant virus, Δ5NB, was generated. This virus had a premature stop codon after the fifth amino acid of the NB sequence leaving the sequence of NA and the upstream nucleotides that control NA translation levels unchanged. Using this viral mutant, we sought to determine a role for NB in vitro or in vivo.

### RESULTS

#### Generation of a recombinant influenza B virus lacking expression of the NB protein

Segment six of a 12 plasmid reverse genetics system based on B/Florida/04/2006 (Elderfield et al., 2015) was modified to create a truncated NB protein. The Δ5NB virus was engineered by the introduction of a premature stop codon after the fifth amino acid of NB coding sequence by site-directed mutagenesis. The NB open reading frame was reduced to five amino acids whilst the NA amino acids remained unchanged (Table 1). Both WT and Δ5NB viruses were rescued and propagated in MDCK cells. We confirmed the lack of NB expression in cells infected with the Δ5NB mutant virus by Western blot of lysates from infected cells using an NB specific monoclonal antibody. This detected a heterogeneous range of NB proteins in lysates of cells infected with WT virus, ranging in size from 15 to 46 kDa as previously described (Williams & Lamb 1988), that were lacking in similar lysates from Δ5NB mutant virus-infected cells. Detection of equivalent amounts of BM2 and NP showed that levels of other viral proteins did not differ between the two viruses (Fig. 1a).

#### The Δ5NB mutation did not affect virus neuraminidase activity

To confirm that the mutations introduced in Δ5NB virus did not affect NA, enzyme activity associated with the mutant virus was measured using three different assays.

For the standard NA enzyme assay that employs a soluble substrate, the MuNANA assay, the WT and mutant viruses were standardized to equivalent p.f.u. and assessed over a range of dilutions for their ability to cleave the MuNANA reagent. There was no significant difference between the two viruses (Fig. 1b).

In the red blood cell (RBC) elution assay, we assessed the viruses’ ability to desialylate red blood cells. The two viruses were mixed with human RBCs at equal HA titres and incubated at 4 °C for 1 h to allow agglutination. The plates were then shifted to 37 °C for 6 h to permit NA activity and observed at regular intervals for the reversal of agglutination.

### Table 1. Nucleotide sequence alterations engineered to generate an influenza B virus that lacks NB expression

The initiating methionines for the NB and NA proteins are single underlined and the mutations that lead to NB truncation are double underlined.

| WT nucleotide sequence | Δ5NB nucleotide sequence | WT NB amino acid sequence | Δ5NB NB amino acid sequence | WT NA amino acid sequence | Δ5NB NA amino acid sequence |
|------------------------|--------------------------|--------------------------|-----------------------------|--------------------------|-----------------------------|
| ATGAACAATGCTACCTCACTATA... | ATGCTACCTCACTATA... | M N N A T F N Y... | M N N A T STOP | M L P S T L... | M L P S T L... |
haemagglutination, which would indicate desialylation of RBCs by the viral NA. If virus eluted from the RBCs they formed a pellet. This effect was more evident at high titres of virus where more NA was present in the well. An end point titre for elution was measured. The two viruses exhibited the same degree of elution at all time points (Fig. 1c).

The mucus inhibition assay measured the ability of the viral NA to cleave abundant sialic acids found in mucus, which can act as decoy receptors, delaying viral infection (Blumenkrantz et al., 2013). Mucus was harvested from the apical surface of well differentiated human airway epithelial (HAE) cell cultures. Diluted mucus was mixed with 100 p.f.u. of each virus prior to inoculating MDCK cells. During incubation at 37 °C on the MDCK cells, the viral NA cleaved sialic acids in mucus enabling infection of the cell monolayer. The infectivity remaining was determined by comparing the number of plaques formed by virus in the presence and absence of mucus. No significant difference in ability to overcome mucus inhibition was observed between the WT and ΔNB virus (Fig. 1d).

Collectively, these results demonstrate that the Δ5NB mutation did not affect NA activity.
**Δ5NB influenza B virus displayed no growth attenuation in a variety of cell types**

In order to measure any effect of loss of NB protein on virus replication kinetics we used human airway-derived Calu-3 cell cultures or primary HAE cell cultures, the latter containing a mixture of ciliated and non-ciliated cells types, with an air interface at the apical surface onto which mucus is secreted. In initial experiments each cell system was inoculated by each virus type in separate wells at an equal m.o.i. and the comparative growth was assessed at set time points by plaque assay on MDCK cells. Both systems were highly permissive for influenza B virus replication with peak titres in excess of $10^7$ p.f.u. ml$^{-1}$ in Calu-3 and $10^8$ p.f.u. ml$^{-1}$ in HAE cultures. Δ5NB virus was not attenuated in either cell system (Fig. 2a, b). Consensus whole genome sequencing of virus generated during multi-step replication confirmed no sequence variation between the WT and Δ5NB viruses, except for the specifically introduced truncation.

Competition assays have increasingly been used to assess small variations in fitness between two influenza viruses not observable by traditional viral growth curves (Brookes et al., 2011; Guarnaccia et al., 2013; Yen et al., 2014). To establish whether lack of NB has a fitness cost for the Δ5NB mutant virus compared with the WT virus, we infected HAE cells with a mixture of 20 % WT and 80 % Δ5NB virus at a final m.o.i. of 0.001. After multi-cycle replication over several days, the relative abundance of the two genotypes in virus harvested from the apical surface was measured using a pyrosequencing reaction. At no time point was there a statistically significant difference in the ratio of WT to Δ5NB from the ratio of genotypes in the input inoculum; after 4 days replication the Δ5NB genotype was still present at 80 % of the RNA population (Fig. 2c). These results indicated that the NB protein did not offer a selective advantage* in vitro* even in a complex cell culture system in which deficiency in NA is readily measured (Brookes et al., 2011).

![Fig. 2](attachment:image.png)

**Fig. 2.** Growth kinetics of virus lacking NB expression on human derived clonal or primary differentiated cell lines. (a) Influenza B/Florida/04/2006 WT or mutant (Δ5NB) viruses were used to infect Calu-3 cells at a low m.o.i. (0.01). At 24 h intervals the viral titre released was assessed by titration on MDCK cells by plaque assay. (b) Influenza B/Florida/04/2006 WT or mutant (Δ5NB) viruses were used to infect Mucilair HAE cell cultures at a low m.o.i. (0.001). Time points were taken by the addition of media to the apical surface and after 30 min the media was removed and the viral titre was assessed by titration on MDCK cells by plaque assay. (c) Competition assay assessing the growth kinetics of virus lacking NB expression on human differentiated primary cell cultures. Influenza B/Florida/04/2006 WT or mutant (Δ5NB) viruses were used to infect Mucilair HAE cell cultures at an m.o.i. of 0.001 with a mixture of 20 % WT and 80 % Δ5NB virus. At 24, 48 and 72 h post-infection, virus released from apical surface was collected in 200 μl of DMEM and after RNA extraction subjected to pyrosequencing to assess the relative percentages of the WT and truncated NB forms.
The Δ5NB recombinant virus is not attenuated in mice in vivo

C57BL/6 mice were infected intranasally with 4.5 \times 10^5 p.f.u. of either WT or Δ5NB virus. The weight loss of the mice was monitored daily. Viral titre, IFN-α and IL-1β in the lungs were determined on days 2, 3 and 4 post-infection. As shown in Fig. 3(a), the two viruses replicated well in mouse lungs, with the Δ5NB displaying slightly higher growth 3 days post-infection (P = 0.007) (Multiple t-test, Holm-Sidak method). As a gross measurement of pathology, weight loss was monitored (Fig. 3b). On all days, mice infected with the WT virus displayed a slightly greater weight loss but the difference between the two groups was not significant (Multiple t-test, Holm-Sidak method).

As an indication of the innate immune response, IFN-α in the mouse lungs was measured at days 2, 3 and 4 post-infection. Significant production of IFN-α in the murine lungs was only evident on day 2 after infection. There was no difference in the interferon levels in the mice infected with WT virus or those infected with the Δ5NB virus, except a slight increase for the Δ5NB infected mice on day 4 (P = 0.005) (Multiple t-test, Holm-Sidak method) (Fig. 3c). Activation of the inflammasome was assessed by measuring levels of IL-1β. Levels of pro-IL1β and total IL-1β (pro form plus activated form) were measured. Both sets of infected mice had higher total IL-1β levels in their lungs than the mock infected animals and this was significant at all days measured (Multiple t-test, Holm-Sidak method). Total IL-1β protein levels tended to be higher in the lungs of mice infected by Δ5NB virus, but this difference was not significant.

Virus lacking NB expression replicates in ferrets and is transmitted by the respiratory droplet route

We tested whether the loss of NB affected replication within a single host or transmission onwards to a new host by inoculating ferrets with a mixture of WT and Δ5NB viruses, and monitoring the ratio of genotypes within and between hosts using pyrosequencing. Four donor ferrets were inoculated with a 1 : 1 ratio of a total of 10^6 p.f.u. WT and Δ5NB virus. All four donors were robustly infected with the virus mixture and shed infectious virus in their nasal wash over the following 6 or 7 days. Peak viral titres were shed on day 2 and were between 10^5 and 10^6 p.f.u. ml^-1 nasal wash. Shedding followed a biphasic kinetic profile similar to that we have previously reported for ferrets infected...
with influenza A viruses (Roberts et al., 2011) (Fig. 4a).
Pyrosequencing of RNA isolated from the daily nasal washes showed that the relative proportions of the two virus genotypes did not vary by more than 11% from the starting mix in any of the four directly inoculated hosts and the direction of the small variation was sometimes to favour wild-type genomes encoding full NB and sometimes Δ5NB mutant genomes (Fig. 4b, c).

Only one of the four respiratory droplet (RD) exposed sentinel animals acquired infection following exposure to the infected donor. Pyrosequencing of the nasal washes from this animal revealed that the virus it had acquired was uniquely the Δ5NB genotype (Fig. 4b). This infected recipient continued to shed Δ5NB virus for 4 days from day 6 to day 9 after it was first exposed. Peak titre in nasal wash from this animal was 10^5 p.f.u. ml⁻¹.

DISCUSSION
The NB protein is absolutely conserved across influenza B viruses, a finding that might indicate it is required for effective replication or transmission. However, our ability to rescue and propagate a recombinant influenza B virus that lacks expression of NB supports the previous conclusion from Hatta et al. (Hatta & Kawaoka, 2003) that NB is dispensable for virus replication in vitro. The design of our mutant virus allowed us to investigate the unique role of NB because we abrogated NB expression with no concomitant effect on the NA function or activity. Although the set of experiments we describe here does not elucidate the function of NB, it does show that NB is not required for replication or transmission of influenza B virus in vitro or in vivo in mice or ferret models.

Previously, loss of NB was correlated with attenuation of replication in vivo in the mouse lung and nasal turbinate and an increase in MLD₅₀, but it could not be excluded that this phenotype arose from a change in NA expression. In our study with an NB mutation that did not compromise NA, there were minimal differences in viral titre and weight loss and only slightly higher levels of IFN-α in the mice infected with the truncated NB protein. We looked carefully at the levels of IL-1β that result

---

**Fig. 4.** Infection of ferrets with influenza B virus. Four ferrets (D1–D4) were inoculated with 10⁴ p.f.u. of an equal mixture WT and truncated NB virus. At 1 day post-infection, four naive ferrets were placed in adjacent cages as respiratory droplet (RD) sentinels (RD1–RD4). (a) Infectious virus titres shed in nasal wash collected each day after infection or exposure established by plaquing on MDCK cells. (b) The relative proportions of the two virus genotypes in daily nasal washes from a paired donor ferret D4 and infected exposed ferret RD4 assessed by pyrosequencing. (c) The relative proportions of the two virus genotypes in daily nasal washes from the remaining three donor ferrets D1, D2 and D3.
from activation of the inflammasome response because other small hydrophobic viral proteins have been implicated in regulation of inflammasomes (Triantafilou et al., 2013). For example, deletion of the SH protein of respiratory syncytial virus, RSV, which is similar in size and domain distribution to NB, led to increased induction of proinflammatory cytokines including IL-1β, and deletion of SH is an attenuation strategy for bovine and human RSV vaccines under development (Karron et al., 2005; Taylor et al., 2014). On the other hand, the ion channel proteins of other viruses such as M2 of influenza A and E protein of the coronavirus SARS, appear to stimulate the inflammasome and their deletion leads to a decreased IL-1β response (Ichinohe et al., 2010; Nieto-Torres et al., 2014). In our experiments, loss of NB expression had a marginal effect on IL-1β expression in the mouse lung. We cannot exclude that a role for NB in modulating inflammasome activation was masked in the mouse model by other factors, or that the effects of NB are strain, host species or cell type specific for this human pathogen.

Very recently, Kim et al. published the first study of transmission of influenza B virus in ferrets (Kim et al., 2015). In line with our data, they also report low transmission efficiency of the B/Florida/04/2006 virus in the ferret model, in contrast to a more efficient influenza B virus RD transmission previously reported between guinea pigs (Pica et al., 2012). The frequency of transmission events we recorded between RD exposed ferrets was surprisingly low, at just one of four exposed animals acquiring infection. We do not yet know if this observation will prove common to a number of influenza B viruses or whether transmission efficiency varies amongst different influenza B virus strains. The influenza B virus we used replicated well in the upper respiratory tract of ferrets and in well differentiated cultures of ferret airway cells (Elderfield et al., 2015). The low transmission efficiency of a seasonal influenza virus suggests either that this animal model does have limitations for the study of influenza B viruses, or that some successful human influenza viruses are not necessarily transmitted primarily by this RD route. As far as the NB protein is concerned, we found that in the single transmission event we did record, the virus that transmitted was uniquely of the genotype that lacked expression of NB. Because we set up mixed infections and both mutant and wild-type virus were replicating simultaneously in the donor animals we cannot absolutely exclude that the Δ5NB virus genome was not complemented by wild-type NB protein during the transmission event. However, our data unequivocally show that NB is not required for replication in the ferret model.

A recent paper also used a reverse genetics approach to probe for a role for NB. Rather than creating a completely null mutant, they chose to mutate the cysteolic tail of the protein and in particular abrogate the post-translational modification of palmitoylation at residue 49 from cysteine to serine (Demers et al., 2014). Surprisingly, in view of our data and that of Hatta et al. that suggested no role in vitro for NB, Demers et al. found that their palmitoylation mutant was attenuated for replication in MDCK cells. It may be that the continued expression of an unnecessary and mutated membrane protein interfered with the normal assembly of virus particles, but whether this result verifies a role for the non-mutated NB protein in wild-type influenza virus infections in vitro is not clear.

Bearing in mind the absolute conservation of NB in all influenza B viruses isolated from clinical cases and even in strains such as influenza B/Lee/40 that have been passaged in eggs and cell culture for more than 75 years, it is highly likely that this protein does serve a role for the virus. However, using current technologies we have been unable to measure a fitness cost in viruses engineered to lack the protein either in vitro or in vivo.

**METHODS**

**Cells.** MDCK cell line and the Human lung adenocarcinoma derived cell line (CALU-3) were maintained in DMEM (Gibco Life Technologies) supplemented with 10 % fetal bovine serum, non-essential amino acids and penicillin/streptomycin (Gibco Life Technologies) at 37 °C with 5 % CO₂ and originated from the ATCC. The Human Airway Epithelial cells (Muclair HAE) were purchased from Epithelix, and were maintained with the proprietary Muclair medium.

**Viruses.** The B/Florida/04/2006 virus was rescued by reverse genetics from plasmids containing cDNA synthesized de novo directly from the database sequence (GenBank Accessions: CY033876, CY033877, CY033878, CY033879, CY033880, CY033881, CY033882, CY033883) (Elderfield et al., 2015); the Δ5NB mutant was generated by site-directed mutagenesis of the segment six plasmid. The viruses were cultured and titred in triplicate by plaque assay on MDCK cells.

**Cell infections.** For growth kinetic experiments in CALU-3 cells, the cells were washed with PBS, virus was added at an m.o.i. of 0.001 in DMEM. The inoculated cells were incubated for 1 h at 37 °C prior to removal of the inoculum, washed with PBS and overlaid with DMEM containing NEAA, P/S and 1 µg/ml TPCK-trypsin (Worthington Biosciences). Time points were taken at 24, 48 and 72 h post-infection. For the growth kinetics and competition assays in human airway epithelial cultures, the apical surfaces of the HAE cell cultures were washed by a 30 min incubation in 250 µl of DMEM. After removal of the medium, virus was added at an m.o.i. of 0.001 (for the competition assay with a mixture of 20 % WT and 80 % ΔNB virus) in a volume of 200 µl of DMEM. After 1 h, the inoculum was removed and the cell layer washed with DMEM. The cultures were incubated at 37 °C at 5 % CO₂ and at 24, 48, 72 and 96 h post-infection, virus released from apical surface was collected in 200 µl DMEM.

**Virus sequencing.** Viral RNA was extracted using the Qiagen QIAmp RNA kit. Reverse transcription was conducted using random hexamers and Superscript III (Invitrogen). DNA amplification was conducted using KOD polymerase (Novagen) and non-coding region segment specific oligomers. DNA bands generated were excised from agarose and cleaned using a Qiagen gel extraction kit. Sequencing was conducted by the GATC sequencing service using the previously mentioned oligomers and additional internal oligomers. The data generated was analysed by alignment using Geneious software. All oligomer sequences are available on request.
**Ferret infections.** Animal studies were conducted as previously described (van Doremalen et al., 2011) Female ferrets (14–16 weeks old) were used. Body weight was measured daily. After acclimatization the ferrets were anaesthetized with ketamine (22 mg kg⁻¹) and xylazine (0.9 mg kg⁻¹) then inoculated intranasally with 10⁶ p.f.u. of a mix of the two RG variants of the B/Florida/04/2006 virus diluted in DMEM (0.1 ml per nostril). All animals were nasal washed daily, while conscious, by instilling 2 ml PBS into the nostrils, and the expectorate was collected in 250 ml centrifuge tubes. Infectious virus was titrated by plaque assay of the nasal wash on confluent MDCK cells.

**Mouse infections.** Female C57BL/6 mice (6–8 weeks old), anaesthetized with isoflurane, were intranasally infected with 40 μl containing 4.5 x 10⁶ p.f.u. of WT or Δ5NB virus or with 40 μl of PBS. Lungs were isolated and homogenized in 1 ml of PBS using the Minilys homogenizer (Bertin Technologies) and the Precellsy Ceramic kit 1.4 mm (PeqLab). Virus titres in the lungs were determined by plaque assay on MDCK cells.

**ELISA.** To detect the cytokines in the homogenized mouse lungs, the VeriKine Mouse Interferon Alpha ELISA kit (Pbl Interferon Source) was used to determine IFN-α levels, and R & D systems Quantikine ELISA kit for IL-1β.

**SDS-PAGE and Western blots.** MDCK cells were inoculated with B/Florida/04/2006 WT, Δ5NB or PBS at an m.o.i. of 3 and incubated overnight at 37 °C. The cells were then lysed and the proteins were separated on a 12 % SDS-PAGE gel and then transferred to a nylon membrane (Micron Separations). The membrane was blocked in Odyssey blocking buffer (LI-COR Biosciences) and then stained with a mouse anti-NB monoclonal antibody (a kind gift from Dhan Samuel PHE Colindale UK) and rabbit anti-BM2 (Jackson Immunoresearch Laboratories) at a 1:70 diluted mucus or virus diluent (PBS + 0.35 % BSA), these mixtures were used to infect confluent MDCK cells (in triplicate). At 1 h post-infection, the cells were washed with PBS and overlaid with plaque overlay media. After 72 h, the cells were fixed and stained with crystal violet and the plaques counted. The infectivity remaining was calculated as the percentage of virus in mucus over the virus in diluent alone.

**RBC elution assay.** 16 HA units of the B/Florida/04/2006 WT or Δ5NB virus were serially diluted twofold in PBS in triplicate in a 96-well plate. 50 μl of 0.5 % fresh human RBCs were added and the plate was incubated at 4 °C for 1 h before a temperature shift to 37 °C for 4 h, the elutions were read hourly until the end point at 6 h.

**ACKNOWLEDGEMENTS**

This work was funded by NC3Rs grants G1000033/1 and NC/K00042X/1, by Wellcome Trust programme grant 087039/Z/08/Z and in part by Crucell NV Netherlands. Animal work was performed under UK Home Office Licence, PPL/70/6643. We are grateful for the expert assistance from the Imperial College London central biological services team. We thank John Tregoning and Ryan Russell for advice about IL-1β.

**REFERENCES**

Belshe, R. B. (2010). The need for quadrivalent vaccine against seasonal influenza. *Vaccine* 28 (Suppl 4), D45–D53.

Betakova, T., Nermut, M. V. & Hay, A. J. (1996). The NB protein is an integral component of the membrane of influenza B virus. *J Gen Virol* 77, 2689–2694.

Blumenkrantz, D., Roberts, K. L., Shelton, H., Lycett, S. & Barclay, W. S. (2013). The short stalk length of highly pathogenic avian influenza H5N1 virus neuraminidase limits transmission of pandemic H1N1 virus in ferrets. *J Virol* 87, 10539–10551.

Brassard, D. L., Leser, G. P. & Lamb, R. A. (1996). Influenza B virus NB glycoprotein is a component of the virion. *Virology* 220, 350–360.

Brookes, D. W., Miah, S., Lackenby, A., Hartgroves, L. & Barclay, W. S. (2011). Pandemic H1N1 2009 influenza virus with the H275Y oseltamivir resistance neuraminidase mutation shows a small compromise in enzyme activity and viral fitness. *J Antimicrob Chemother* 66, 466–470.

Demers, A., Ran, Z., Deng, Q., Wang, D., Edman, B., Lu, W. & Li, F. (2014). Palmitoylation is required for intracellular trafficking of influenza B virus NB protein and efficient influenza B virus growth in vitro. *J Gen Virol* 95, 1211–1220.

Elderfield, R. A., Parker, L., Stilwell, P., Roberts, K. L., Schepelmann, S. & Barclay, W. S. (2015). Ferret airway epithelial cell cultures support efficient replication of influenza B virus but not mumps virus. *J Gen Virol* 96, 2092–2098.

Fischer, W. B., Pitkeathly, M., Wallace, B. A., Forrest, L. R., Smith, G. R. & Sansom, M. S. (2000). Transmembrane peptide NB of influenza B: a simulation, structure, and conductance study. *Biochemistry* 39, 12708–12716.

Fischer, W. B., Pitkeathly, M. & Sansom, M. S. (2001). Amantadine blocks channel activity of the transmembrane segment of the NB protein from influenza B. *Eur Biophys J* 30, 416–420.

Gannagé, M., Dormann, D., Albrecht, R., Dengjel, J., Torossi, T., Rämer, P. C., Lee, M., Strowig, T., Arrey, F. & other authors (2009). Matrix protein 2 of influenza A virus blocks apoptosis fusing with lysosomes. *Cell Host Microbe* 6, 367–380.

Guarnaccia, T., Carolan, L. A., Mauer-Stroh, S., Lee, R. T. C., Job, E., Reading, P. C., Petrie, S., McCaw, J. M., McVernon, J. & other authors
(2013). Antigenic drift of the pandemic 2009 A(H1N1) influenza virus in a ferret model. *PLoS Pathog* 9, e1003354.

Hatta, M. & Kawaoka, Y. (2003). The NB protein of influenza B virus is not necessary for virus replication in vitro. *J Virol* 77, 6050–6054.

Horvath, C. M., Williams, M. A. & Lamb, R. A. (1990). Eukaryotic coupled translation of tandem cistrons: identification of the influenza B virus BM2 polypeptide. *EMBO J* 9, 2639–2647.

Hughey, P. G., Roberts, P. C., Holsinger, L. J., Zebedee, S. L., Lamb, R. A. & Comps, R. W. (1995). Effects of antibody to the influenza A virus M2 protein on M2 surface expression and virus assembly. *Virology* 212, 411–421.

Ichinohe, T., Pang, I. K. & Iwasaki, A. (2010). Influenza virus activates inflammasomes via its intracellular M2 ion channel. *Nat Immunol* 11, 404–410.

Imai, M., Watanabe, S., Ninomiya, A., Obuchi, M. & Odagiri, T. (2004). Influenza B virus BM2 protein is a crucial component for incorporation of viral ribonucleoprotein complex into virions during virus assembly. *J Virol* 78, 11007–11015.

Iwatsuki-Horimoto, K., Horimoto, T., Noda, T., Kiso, M., Maeda, J., Watanabe, S., Muramoto, Y., Fuji, K. & Kawaoka, Y. (2006). The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. *J Virol* 80, 5233–5240.

Jackson, D., Elderfield, R. A. & Barclay, W. S. (2011). Molecular studies of influenza B virus in the reverse genetics era. *J Gen Virol* 92, 1–17.

Jackson, D., Zürcher, T. & Barclay, W. (2004). Reduced incorporation of the influenza B virus BM2 protein in virus particles decreases infectivity. *Virology* 322, 276–285.

Karron, R. A., Wright, P. F., Belshe, R. B., Thumar, B., Casey, R., Newman, F., Polack, F. P., Randolph, V. B., Deatly, A. & other authors (2005). Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. *J Infect Dis* 191, 1093–1104.

Kim, E.-H., Park, S.-J., Kwon, H.-I., Kim, S. M., Kim, Y.-I., Song, M.-S., Choi, E.-J., Pascua, P. N. O. & Choi, Y.-K. (2015). Mouse adaptation of influenza B virus increases replication in the upper respiratory tract and results in droplet transmissibility in ferrets. *Sci Rep* 5, 15940.

McCown, M. F. & Pekosz, A. (2005). The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. *J Virol* 79, 3595–3605.

Nieto-Torres, J. L., DeDiego, M. L., Verdiá-Báguena, C., Jimenez-Guardeño, J. M., Regla-Nava, J. A., Fernandez-Delgado, R., Castaño-Rodríguez, C., Alcaraz, A., Torres, J. & other authors (2014). Severe acute respiratory syndrome coronavirus envelope protein ion channel activity promotes virus fitness and pathogenesis. *PLoS Pathog* 10, e1004077.

Pica, N., Chou, Y.-Y., Bouvier, N. M. & Palese, P. (2012). Transmission of influenza B viruses in the guinea pig. *J Virol* 86, 4279–4287.

Pinto, L. H., Holsinger, L. J. & Lamb, R. A. (1992). Influenza virus M2 protein has ion channel activity. *Cell* 69, 517–528.

Premkumar, A., Ewart, G. D., Cox, G. B. & Gage, P. W. (2004). An amino-acid substitution in the influenza-B NB protein affects ion-channel gating. *J Membr Biol* 197, 135–143.

Roberts, K. L., Shelton, H., Scull, M., Pickles, R. & Barclay, W. S. (2011). Lack of transmission of a human influenza virus with avian receptor specificity between ferrets is not due to decreased virus shedding but rather a lower infectivity in vivo. *J Gen Virol* 92, 1822–1831.

Rossman, J. S., Jing, X., Leser, G. P. & Lamb, R. A. (2010). Influenza virus M2 protein mediates ESCRT-independent membrane scission. *Cell* 142, 902–913.

Rota, P. A., Wallis, T. R., Harmon, M. W., Rota, J. S., Kendal, A. P. & Nerome, K. (1990). Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. *Virology* 175, 59–68.

Shaw, M. W., Choppin, P. W. & Lamb, R. A. (1983). A previously unrecognized influenza B virus glycoprotein from a bicistronic mRNA that also encodes the viral neuraminidase. *Proc Natl Acad Sci U S A* 80, 4879–4883.

Sunstrom, N. A., Premkumar, L. S., Premkumar, A., Ewart, G., Cox, G. B. & Gage, P. W. (1996). Ion channels formed by NB, an influenza B virus protein. *J Membr Biol* 150, 127–132.

Taylor, G., Wyld, S., Valarcher, J.-F., Guzman, E., Thom, M., Widdison, S. & Buchholz, U. J. (2014). Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves. *J Gen Virol* 95, 1244–1254.

Triantafilou, K., Kar, S., Vakakis, E., Kotecha, S. & Triantafilou, M. (2013). Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. *Thorax* 68, 66–75.

van Doremalen, N., Shelton, H., Roberts, K. L., Jones, I. M., Pickles, R. J., Thompson, C. I. & Barclay, W. S. (2011). A single amino acid in the HA of pH1N1 2009 influenza virus affects cell tropism in human airway epithelium, but not transmission in ferrets. *PLoS One* 6, e25755.

Williams, M. A. & Lamb, R. A. (1986). Determination of the orientation of an integral membrane protein and sites of glycosylation by oligonucleotide-directed mutagenesis: influenza B virus NB glycoprotein lacks a cleavable signal sequence and has an extracellular NH2-terminal region. *Mol Cell Biol* 6, 4317–4328.

Williams, M. A. & Lamb, R. A. (1988). Polylactosaminoglycan modification of a small integral membrane glycoprotein, influenza B virus NB. *Mol Cell Biol* 8, 1186–1196.

Williams, M. A. & Lamb, R. A. (1989). Effect of mutations and deletions in a bicistronic mRNA on the synthesis of influenza B virus NB and NA glycoproteins. *J Virol* 63, 28–35.

Yen, H.-L., Zhou, J., Choy, K.-T., Sia, S. F., Teng, O., Ng, I. H., Fang, V. J., Hu, Y., Wang, W. & other authors (2014). The R292K mutation that confers resistance to neuraminidase inhibitors leads to competitive fitness loss of A/Shanghai/1/2013 (H7N9) influenza virus in ferrets. *J Infect Dis* 210, 1900–1908.